article thumbnail

STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug

STAT

Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits.

article thumbnail

STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more

STAT

Back in 2004, Gilead explained its decision by maintaining the medicines were not sufficiently different, but internal documents produced in court suggested the company made this move in order to maximize profits. Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EMA revises guidance on nitrosamine impurities

European Pharmaceutical Review

The assessment report of the Committee for Medicinal Products for Human Use (CHMP)’s Article 5(3) of Regulation (EC) No 726/2004 opinion on nitrosamine impurities in human medicinal products offers guidance and recommendations on mitigation and prevention of nitrosamine-contaminated human medicinal products.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 The prerequisite to present statistically significant evidence for having efficacies of clinical relevance is crucial because FDA requires “adequate and well-controlled” multicentre clinical studies on any new drug candidate to document and support its safety and efficacy, and imposes the maximum level of scrutiny prior to approval.

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.

article thumbnail

The Febrile Infant: Incorporating the 2021 American Academy of Pediatrics guidelines

ALiEM - Pharm Pearls

Children 29 days or older with fever from a documented viral source can be managed according to their clinical presentation and can go outside the algorithm. This requires a documented positive viral swab and not just a presentation consistent with a viral syndrome. 2004 Mar 10;291(10):1261-2. References: Roberts KB.

Hospitals 360
article thumbnail

Masterclass: Fundamentals of Key Account Management (KAM)

PharmaState Academy

He is an awe-inspiring peronality who has exceptional experiences in building and leading Institutional Sales, Key Account Management , Strategy & Planning , Market Access, Tender Business, New Product Inclusion, Document & Pricing strategy and much more.